Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart sensors could track brain disease at home

NCT ID NCT07240805

Knowledge-focused Sponsor: BioSensics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 5 times

Summary

This study will test whether wearable sensors can accurately monitor movement problems in people with progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB). About 60 participants will wear small sensors on their chest, ankles, and wrists while doing simple tasks like walking and hand movements, both in the clinic and at home for 14 days. The goal is to see if these sensors can provide reliable, at-home monitoring that could be used in future clinical trials for these rare brain diseases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
wearable sensors (PAMSys pendant, ankle, and wrist sensors)
What this could lead to
If successful, this could enable frequent, at-home monitoring of disease symptoms, making future clinical trials more efficient and less burdensome for patients.
What could go wrong
This is an early-stage validation study with only 60 participants, so the sensors may not prove accurate or practical for widespread use. The results are observational and won't directly treat or cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals with clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB

Ages

40 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants aged 40-89 meeting clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB. * Able to be present for all study procedures, complete questionnaires and assist during home data collection. * Eligible participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment. * Must have a caregiver or study partner who is willing and able to assist with all study-related procedures. * Ambulatory (able to take 10 steps with minimal support such as use of a cane) Exclusion Criteria: * Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment. * History of frequent falls defined as more than 5 falls per month, will not be eligible to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia with lewy bodies (DLB) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

familial spontaneous pneumothorax Lewy body dementia Lewy Body Disease progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia with lewy bodies (DLB) Lewy body dementia (LBD) Lewy body disease Progressive supranuclear palsy (PSP) PSP

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins University School of Medicine

    Lutherville, Maryland, 21093, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.